natgillin/translations-raw huggingface dataset:
Brivaracetam film-coated tablets, oral solution and solution for intravenous injection show the same AUC, while the maximum plasma concentration is slightly higher after intravenous administration. 
Filmsko obložene tablete brivaracetama, peroralna raztopina in raztopina za intravensko injiciranje kažejo enak AUC, medtem ko je največja plazemska koncentracija po intravenski uporabi rahlo večja.
* Based on physician assessment of need for seizure control. 
* Na podlagi zdravnikove ocene potrebe po obvladovanju epileptičnih napadov.
Other medicines and Briviact 
Druga zdravila in zdravilo Briviact
Doses in patients from 4 years of age were defined by weight-based dose adaptations which have been established to achieve similar plasma concentrations to the ones observed in adults taking efficacious doses (section 5.2). 
Odmerki pri bolnikih od 4. leta starosti so bili opredeljeni s prilagoditvijo odmerka na podlagi telesne mase, ugotovljeni tako, da so bile dosežene koncentracije v plazmi podobne tistim pri odraslih, ki so jemali učinkovite odmerke (glejte poglavje 5.2).
Due to its lipophylicity (Log P) brivaracetam has high cell membrane permeability. 
Zaradi svoje lipofilnosti (log P) ima brivaracetam visoko sposobnost prehajanja skozi celično membrano.
Hypersensitivity to the active substance or other pyrrolidone derivatives or to any of the excipients listed in section 6.1. 
Preobčutljivost na zdravilno učinkovino ali druge derivate pirolidona ali katero koli pomožno snov, navedeno v poglavju 6.1.
Risk related to brivaracetam 
Tveganja, povezana z brivaracetamom
Your doctor may then decide to adjust your dose to find the best dose for you. 
Zdravnik se lahko nato odloči, da vam prilagodi vaš odmerek tako, da najde odmerek, ki vam najbolj ustreza.
- St John's wort (also known as Hypericum perforatum) - a herbal medicine used to treat depression and anxiety as well as other conditions. 
šentjanževka (znana tudi kot Hypericum perforatum) - ki je zdravilo rastlinskega izvora in se uporablja za zdravljenje depresije, tesnobe ter drugih stanj.
Levetiracetam None 
Nič levetiracetam Nič
Briviact is indicated as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy. 
Zdravilo Briviact je indicirano za dopolnilno zdravljenje parcialnih epileptičnih napadov s sekundarno generalizacijo ali brez nje pri odraslih, mladostnikih in otrocih od 4. leta starosti z epilepsijo.
In rats, brivaracetam was shown to readily cross the placenta and to be excreted in milk of lactating rats with concentrations similar to maternal plasma levels. 
Pri podganah se je izkazalo, da brivaracetam zlahka prehaja skozi placento in se izloča v mleko doječih podgan v koncentracijah, ki so podobne materinim ravnem v plazmi.
The daily dose of brivaracetam ranged from 5 to 200 mg/day across these studies. 
Dnevni odmerek brivaracetama je bil v teh študijah od 5 do 200 mg/dan.
If you stop taking Briviact 
Če ste prenehali jemati zdravilo Briviact
In vitro, brivaracetam was not an inhibitor of the CYP1A2, 2A6, 2B6, 2C8, 2C9, 2D6, 3A4, or the transporters P-gp, BCRP, BSEP MRP2, MATE-K, MATE-1, OATP1B1, OATP1B3, OAT1 and OCT1 at clinically relevant concentrations. 
In vitro, pri klinično pomembnih koncentracijah, brivaracetam ni bil zaviralec CYP1A2, 2A6, 2B6, 2C8, 2C9, 2D6, 3A4 ali prenašalcev P-gp, BCRP, BSEP MRP2, MATE-K, MATE-1, OATP1B1, OATP1B3, OAT1 in OCT1.
The effect of the interactions on the plasma concentration is summarised in table 1 (increase is indicated as “↑” and decrease as “↓”, area under the plasma concentration versus time curve as “AUC”, maximum observed concentration as Cmax). 
Učinek interakcij na plazemsko koncentracijo je povzet v preglednici 1 (povečanje je označeno z ↑, zmanjšanje z ↓, površina pod krivuljo plazemske koncentracije v odvisnosti od časa kot AUC, največja opažena koncentracija kot Cmax).
After 1 week of treatment at 50 mg/day, a final week of treatment at the dose of 20 mg/day is recommended. 
Po 1 tednu zdravljenja s 50 mg/dan je v zadnjem tednu zdravljenja priporočen odmerek 20 mg/dan.
Brivaracetam plasma concentrations may increase when coadministered with CYP2C19 strong inhibitors (e.g. fluconazole, fluvoxamine), but the risk of a clinically relevant CYP2C19-mediated interaction is considered to be low. 
Plazemske koncentracije brivaracetama se lahko povečajo, če se ta daje sočasno z močnimi zaviralci CYP2C19 (npr. flukonazol, fluvoksamin), vendar se tveganje klinično pomembnih interakcij, posredovanih s CYP2C19, smatra za nizko.
Each film-coated tablet contains 10 mg, 25 mg, 50mg, 75 mg, or 100 mg brivaracetam. 
Ena filmsko obložena tableta vsebuje 10 mg, 25 mg, 50 mg, 75 mg ali 100 mg brivaracetama.
- Intravenous infusion: brivaracetam may be diluted in a compatible diluent and administered as a 15-minute intravenous infusion (see section 6.6). 
- Intravenska infuzija: brivaracetam lahko razredčite s kompatibilnim topilom in dajete kot 15minutno intravensko infuzijo (glejte poglavje 6.6).
- For the long term treatment with Briviact, your doctor will ask to you to take Briviact tablets or oral solution. 
- Za dolgotrajno zdravljenje z zdravilom Briviact vam bo zdravnik naročil, da vzamete tablete ali peroralno raztopino zdravila Briviact.
In healthy subjects, coadministration with the strong enzyme inducer rifampicin (600 mg/day for 5 days), decreased brivaracetam area under the plasma concentration curve (AUC) by 45 %. 
Pri zdravih preskušancih je sočasno dajanje z močnim induktorjem encimov rifampicinom (600 mg/dan, 5 dni) zmanjšalo površino pod krivuljo plazemske koncentracije (AUC - area under curve) brivaracetama za 45 %.
Brivaracetam 200mg/day may increase plasma concentrations of medicinal products transported by OAT3. 
Brivaracetam 200 mg/dan lahko poveča plazemske koncentracije učinkovin, ki se prenašajo z OAT3.
- Turn the bottle upside down (figure 5). 
- Steklenico obrnite navzdol (slika 5).
Therefore, starting or ending treatment with St John's wort should be done with caution. 
Zato je treba previdno izvesti začetek ali konec zdravljenja s šentjanževko.
Coadministration with a high-fat meal slowed down the absorption rate (median tmax 3 h) and decreased the maximum plasma concentration (37 % lower) of brivaracetam, while the extent of absorption remained unchanged. 
Sočasno jemanje z obrokom z visoko vsebnostjo maščob upočasni stopnjo absorpcije (mediana čas tmax je 3 h) in zniža največjo plazemsko koncentracijo (za 37 %) brivaracetama, medtem ko je obseg absorpcije nespremenjen.
In safety pharmacology studies, the predominant effects were CNS related (mainly transient CNS depression and decreased spontaneous locomotor activity) seen at multiples (greater than 50 fold) of the pharmacologically active dose of brivaracetam, 2 mg/kg. 
V študijah varnostne farmakologije so bili poglavitni učinki povezani s centralnim živčnim sistemom (predvsem začasna depresija centralnega živčnega sistema in zmanjšana spontana lokomotorična dejavnost), ki je bila opažena pri večkratnikih (več kot 50-krat) farmakološko aktivnega odmerka brivaracetama 2 mg/kg.
The efficacy and tolerability of brivaracetam in paediatric patients less than 4 years of age have not been established (see section 4.2). 
Učinkovitost in prenašanje brivaracetama pri pediatričnih bolnikih, starih manj kot 4 leta, nista bili ugotovljeni (glejte poglavje 4.2).
The primary endpoints in the phase 3 studies were the percent reduction in POS frequency over placebo and the 50 % responder rate based on 50 % reduction in POS frequency from baseline. 
Primarni opazovani dogodek v študijah faze 3 je bilo odstotno zmanjšanje pogostnosti parcialnih napadov v primerjavi s placebom in 50 % stopnja odzivnosti na podlagi 50 % zmanjšanja pogostnosti parcialnih napadov glede na izhodišče.
n = randomised patients who received at least 1 dose of study medication ~ Dose not studied Statistically significant Approximately 20 % of the patients were on concomitant levetiracetam The primary outcome for N01252 did not achieve statistical significance based on the sequential testing procedure. 
n = število randomiziranih bolnikov, ki so prejeli vsaj 1 odmerek preiskovanega zdravila ~ Odmerek, ki ga niso preučevali Statistično pomembno Približno 20 % bolnikov je sočasno prejemalo levetiracetam Primarni rezultat za N01252 ni dosegel statistično pomembnost, ki je temeljila na zaporednih testnih postopkih.
In the short-term clinical studies of brivaracetam in epilepsy patients, there were no cases of completed suicide and suicide attempt, however both have been reported in open-label extension studies (see section 4.4). 
Pri kratkotrajnih kliničnih študijah brivaracetama pri bolnikih z epilepsijo niso zabeležili primerov izvedenih samomorov ali poskusov samomora, vendar so o obojem poročali pri podaljšanih odprtih študijah (glejte poglavje 4.4).
The 5 ml oral syringe must be used in patients weighing less than 20 kg to ensure accurate dosing as the 10 ml oral syringe does not allow accurate measurements of volumes <1 ml. 
5-ml peroralna brizga se mora uporabiti pri bolnikih, ki tehtajo manj kot 20 kg, da se zagotovi natančno odmerjanje, saj natančnega odmerjanja količin <1 ml s peroralno brizgo 10 ml ni mogoče doseči.
Both metabolites, are further metabolised forming a common hydroxylated acid formed predominantly by hydroxylation of the propyl side chain on the carboxylic acid metabolite (mainly by CYP2C9). 
Oba presnovka se nadalje presnavljata v skupno hidroksilirano kislino, ki se tvori predvsem s hidroksilacijo propilne stranske verige na presnovku karboksilne kisline (v glavnem s CYP2C9).
Do not stop taking this medicine unless your doctor tells you to. 
Ne prenehajte jemati tega zdravila, razen če vam tako naroči zdravnik.
Physicians should discuss family planning and contraception with women of childbearing potential taking brivaracetam (see Pregnancy). 
Zdravniki se morajo z ženskami v rodni dobi, ki jemljejo brivaracetam, pogovoriti o načrtovanju družine in kontracepciji (glejte Nosečnost).
Four of these subjects had decreased neutrophil counts at baseline, and experienced additional decrease in neutrophil counts after initiation of brivaracetam treatment. 
Štirje od teh preskušancev so imeli že ob izhodišču zmanjšano število nevtrofilcev, po začetku zdravljenja z brivaracetamom pa je prišlo do dodatnega zmanjšanja števila nevtrofilcev.
Briviact tablets are packaged in blister packs supplied in cardboard boxes containing either 14, 56, 14 x 1 or 100 x 1 film-coated tablets or in multipacks containing 168 (3 packs of 56) film-coated tablets. 
Tablete zdravila Briviact so pakirane v pretisne omote, ki se nahajajo v škatlah, ki vsebujejo po 14, 56, 14 x 1 ali 100 x 1 filmsko obloženo tableto, ali v večkratnih pakiranjih, ki vsebujejo 168 (3 pakiranja po 56) filmsko obloženih tablet.
Recommended starting dose 50 mg/day (or 100 mg/day)* 
Priporočeni začetni odmerek 50 mg/dan (ali 100 mg/dan)*
- Turn the bottle the right way up (figure 9). 
- Obrnite steklenico pokonci (slika 9).
In juvenile rats, brivaracetam exposure levels 6- to 15-fold the clinical AUC exposure at the maximum recommended dose induced developmental adverse effects (i.e. mortality, clinical signs, decreased body weight and lower brain weight). 
Pri mladičih podgan je brivaracetam z ravnjo izpostavljenosti, ki je od 6- do 15-krat višja od klinične izpostavljenosti AUC pri največjem priporočenem odmerku, povzročal neželene razvojne učinke (tj. smrtnost, klinični znaki, manjša telesna masa in manjša masa možganov).
What Briviact is and what it is used for 
Kaj je zdravilo Briviact in za kaj ga uporabljamo
Study N01253 
Študija N01253
A study in subjects with severe renal impairment (creatinine clearance <30 ml/min/1.73 m² and not requiring dialysis) revealed that the plasma AUC of brivaracetam was moderately increased (+21 %) relative to healthy controls, while the AUC of the acid, hydroxy and hydroxyacid metabolites were increased 3-, 4-, and 21-fold, respectively. 
Študija preskušancev s hudo okvaro ledvic (očistek kreatinina < 30 ml/min/1,73 m², niso potrebovali dialize) je pokazala, da je bil plazemski AUC brivaracetama zmerno povišan (+ 21 %) v primerjavi z zdravimi kontroliranimi preskušanci, medtem ko se je AUC kislinskih, hidroksi in hidroksikislinskih presnovkov povečal 3-, 4- oziroma 21-krat.
How to take Briviact oral solution - You can take Briviact oral solution on its own, or dilute it in water or juice shortly before swallowing. 
Kako jemati zdravilo Briviact peroralna raztopina - Zdravilo Briviact peroralna raztopina lahko jemljete samo, ali pa jo razredčite z vodo ali sokom neposredno pred zaužitjem.
Brivaracetam plasma concentrations are decreased when coadministered with strong enzyme inducing AEDs (carbamazepine, phenobarbital, phenytoin) but no dose adjustment is required (see table 1). 
Plazemske koncentracije brivaracetama se zmanjšajo pri sočasnem jemanju antiepileptikov, ki močno inducirajo encime (karbamazepin, fenobarbital, fentoin), vendar prilagoditev odmerka ni potrebna (glejte preglednico 1).
The oral solution contains methyl parahydroxybenzoate (E218), which may cause allergic reactions (possibly delayed). 
Peroralna raztopina vsebuje metilparahidroksibenzoat (E218), ki lahko povzroči alergijske reakcije, (lahko zapoznele).
Follow these steps each time you take Briviact: - Put the oral syringe into the adaptor opening (figure 4). 
Vsakič ko vzamete zdravilo Briviact, upoštevajte naslednje korake: - Vstavite peroralno brizgo v odprtino adapterja (slika 4).
All doses were adjusted by body weight, and did not exceed a maximum of 50 mg/day, 100 mg/day, and 200 mg/day. 
Vsi odmerki so bili prilagojeni na telesno maso in niso presegli največjega odmerka 50 mg/dan, 100 mg/dan in 200 mg/dan.
This may avoid the brivaracetam plasma concentration falling below the efficacy level and prevent breakthrough seizures from occurring. 
S tem se je mogoče izogniti padcu plazemske koncentracije brivaracetama pod raven učinkovitosti in preprečiti pojav prebojnih epileptičnih napadov.
In vitro, brivaracetam is not a substrate of human Pglycoprotein (P-gp), multidrug resistance proteins (MRP) 1 and 2, and likely not organic anion transporter polypeptide 1B1 (OATP1B1) and OATP1B3. 
Brivaracetam in vitro ni substrat za človeški P-glikoprotein (P-gp), proteine odporne proti večim učinkovinam 1 in 2 in verjetno ne za organski anionski prenašalni polipeptid 1B1 (OATP1B1) in OATP1B3.
Brivaracetam did not affect male or female fertility and has demonstrated no teratogenic potential in either rat or rabbit. 
Brivaracetam ni vplival na plodnost samcev ali samic ter pri podganah in kuncih ni kazal teratogenega potenciala.
Very common: may affect more than 1 in 10 people - feeling sleepy or dizzy 
Zelo pogosti: pojavijo se lahko pri več kot 1 od 10 bolnikov - občutek zaspanosti ali omotice
Embryotoxicity was observed in rabbits at a maternal toxic dose of brivaracetam with an exposure level 8-fold the clinical AUC exposure at the maximum recommended dose. 
Embriotoksičnost so opazili pri kuncih pri za mater toksičnem odmerku brivaracetama, pri čemer je bila raven izpostavljenosti 8-kratnik klinične izpostavljenosti AUC pri največjem priporočenem odmerku.
Excipient(s) with known effect: Each ml of solution for injection/infusion contains 3.8 mg sodium. 
Pomožne snovi z znanim učinkom: En ml raztopine za injiciranje/infundiranje vsebuje 3,8 mg natrija.
It is unknown whether brivaracetam is excreted in human breast milk. 
Ni znano, ali se brivaracetam izloča v materino mleko.
10 ml oral syringe provided in the carton to ensure accurate dosing. 
10-ml peroralno brizgo, priloženo v škatli, da zagotovite natančno odmerjanje.
Study N01252 
Študija N01252
No additional safety or tolerability concern was observed (see section 5.1). 
Prav tako niso ugotovili dodatnih zadržkov glede varnosti in prenašanja zdravila (glejte poglavje 5.1).
A maximum daily dose of 150 mg administered in 2 divided doses is recommended for all stages of hepatic impairment (see section 4.4 and 5.2). 
Za vse stopnje okvare jeter je priporočen največji dnevni odmerek 150 mg, razdeljen v 2 enaka odmerka (glejte poglavji 4.4 in 5.2).
This helps to stop your fits coming back or getting worse. 
Tako boste preprečili, da bi se epileptični napadi vrnili ali poslabšali.
The most commonly taken AEDs at the time of study entry were carbamazepine (40.6 %), lamotrigine (25.2 %), valproate (20.5 %), oxcarbazepine (16.0 %), topiramate (13.5 %), phenytoin (10.2 %) and levetiracetam (9.8 %). 
V času študije so najpogosteje jemali karbamazepin (40,6 %), lamotrigin (25,2 %), valproat (20,5 %), okskarbazepin (16,0 %), topiramat (13,5 %), fenitoin (10,2 %) in levetiracetam (9,8 %).
Based on data in adults, no dose adjustment is necessary in paediatric patients with impaired renal function. 
Na podlagi podatkov pri odraslih prilagajanje odmerka pri pediatričnih bolnikih z okvarjenim delovanjem ledvic ni potrebno.
(Omitted from cartons of 14 film-coated tablets) 
(Izpuščeno na zloženkah s 14 filmsko obloženimi tabletami)
Each ml of oral solution contains 239.8 mg sorbitol (E420), 1mg methyl parahydroxybenzoate (E218) and 1.16 mg sodium. 
En ml peroralne raztopine vsebuje 239,8 mg sorbitola (E420), 1 mg metilparahidroksibenzoata (E218) in 1,16 mg natrija.
A pharmacokinetic study in subjects with hepatic cirrhosis (Child-Pugh grades A, B, and C) showed similar increases in exposure to brivaracetam irrespective of disease severity (50 %, 57 % and 59 %), relative to matched healthy controls. 
Farmakokinetična študija pri preskušancih s cirozo jeter (stopnja Child-Pugh A, B in C) je pokazala podobna povečanja izpostavljenosti brivaracetamu ne glede na resnost bolezni (50 %, 57 % in 59 %) v primerjavi z ustreznimi zdravimi kontroliranimi preskušanci (glejte poglavje 4.2).
14 film-coated tablets 56 film-coated tablets 100 x 1 film-coated tablet 14 x 1 film-coated tablet 
14 filmsko obloženih tablet 56 filmsko obloženih tablet 100 x 1 filmsko obložena tableta 14 x 1 filmsko obložena tableta
There were no adverse effects in any of the standard developmental or maturation endpoints. 
Pri standardnih razvojnih in zrelostnih opazovanih dogodkih ni bilo neželenih učinkov.
Briviact solution for injection/infusion can be administered as a bolus injection or as an infusion: 
Briviact raztopino za injiciranje lahko dajete kot bolus ali kot infuzijo:
(Only for outer carton) 
(Samo za škatlo.)
Overall, brivaracetam was efficacious for the adjunctive treatment of partial onset seizures in patients 16 years of age and older between 50 mg/day and 200 mg/day. 
V splošnem je bil brivaracetam učinkovit za dopolnilno zdravljenje parcialnih napadov pri bolnikih, starih 16 let ali več, in pri odmerkih med 50 mg/dan in 200 mg/dan.
The hydrolysis of the amide moiety leading to the carboxylic acid metabolite (34 % of the dose in urine) is supported by hepatic and extra-hepatic amidase. 
Hidrolizo amidnega dela, ki vodi do presnovka v obliki karboksilne kisline (34 % odmerka v urinu), omogoča amidaza v jetrih in izven njih.
- Intravenous bolus: brivaracetam may be administered as an intravenous bolus without dilution. 
- Intravenski bolus: brivaracetam lahko dajete kot intravenski bolus brez razredčenja.
When tested in vitro brivaracetam did not induce CYP1A1/2 but induced CYP3A4 and CYP2B6. 
Pri testiranju in vitro brivaracetam ni induciral CYP1A1/2, ampak je induciral CYP3A4 in CYP2B6.
The adverse reactions most frequently resulting in discontinuation of brivaracetam therapy were dizziness (0.8 %) and convulsion (0.8 %). 
Neželena učinka, o katerih so najpogosteje poročali pri prekinitvi zdravljenja z brivaracetamom, sta bila omotica (0,8 %) in konvulzije (0,8 %).
In case of co-administration of brivaracetam and carbamazepine, the amount of carbamazepine-epoxide excreted in breast milk could increase. 
V primeru sočasnega dajanja brivaracetama in karbamazepina se lahko poveča količina karbamazepin epoksida, ki se izloča v materino mleko.
Following dilution, brivaracetam solution for injection/infusion was found to be physically compatible and chemically stable when mixed with the diluents listed in the section 6.6 for 24 hours and stored in PVC or polyolefin bags at temperature up to 25°C. 
Ugotovili so, da je raztopina brivaracetama za injiciranje/infundiranje po redčenju fizikalno kompatibilna in kemijsko stabilna 24 ur, če je zmešana s topili, naštetimi v poglavju 6.6, in shranjena v vrečah iz PVC-ja ali poliolefina pri temperaturi do 25 °C.
Brivaracetam is cleared by multiple pathways including renal excretion, non-CYP-mediated hydrolysis and CYP-mediated oxidations. 
Brivaracetam se iz telesa čisti po več poteh, vključno z ledvičnim izločanjem, hidrolizo, ki ni posredovana s CYP, in z oksidacijami, posredovanimi s CYP.
The three metabolites are not pharmacologically active. 
Noben od treh presnovkov ni farmakološko aktiven.
Binding to SV2A is believed to be the primary mechanism for brivaracetam anticonvulsant activity. 
Predvideva se, da je vezava na SV2A primarni mehanizem za antikonvulzijsko aktivnost brivaracetama.
The efficacy of brivaracetam for the adjunctive therapy of partial onset seizures (POS) was established in 3 randomized, double-blind, placebo-controlled, fixed-dose, multi-center studies in subjects 16 years of age and older. 
Učinkovitost brivaracetama kot dopolnilnega zdravljenja parcialnih napadov so ugotovili v 3 randomiziranih, dvojno slepih s placebom nadzorovanih multicentričnih študijah s fiksnimi odmerki pri preskušancih, starih 16 let in več.
Briviact film-coated tablets contain lactose (a type of sugar). 
Filmsko obložene tablete Briviact vsebujejo laktozo (vrsto sladkorja).
Upper respiratory tract infections, cough 
Okužbe zgornjih dihal, kašelj
Potential interactions between brivaracetam (50 mg/day to 200 mg/day) and other AEDs were investigated in a pooled analysis of plasma drug concentrations from all phase 2-3 studies in a population pharmacokinetic analysis of placebo-controlled phase 2-3 studies, and in dedicated drugdrug interaction studies (for the following AEDs: carbamazepine, lamotrigine, phenytoin and topiramate). 
Potencialne interakcije brivaracetama (od 50 mg/dan do 200 mg/dan) z drugimi antiepileptiki so preiskovali v združeni analizi plazemskih koncentracij zdravil iz vseh študij faze 2-3 v populacijski farmakokinetični analizi s placebom nadzorovanih študij faze 2-3 in v namenskih študijah interakcij med dvema zdraviloma (za naslednje antiepileptike: karbamazepin, lamotrigin, fentoin in topiramat).
Apart from dose-dependent increases in incidences of somnolence and fatigue brivaracetam 50 mg/day and 100 mg/day had a similar safety profile including CNSrelated AEs and with long-term use. 
Razen povečanj incidence somnolence in utrujenosti, odvisnih od odmerka, je brivaracetam v odmerku 50 mg/dan in 100 mg/dan imel podoben varnostni profil, vključno z neželenimi učinki, povezanimi s centralnim živčnim sistemom, in dolgotrajno uporabo.
Brivaracetam is primarily metabolized by hydrolysis of the amide moiety to form the corresponding carboxylic acid (approximately 60 % the elimination), and secondarily by hydroxylation on the propyl side chain (approximately 30 % the elimination). 
Brivaracetam se primarno presnavlja s hidrolizo amidnega dela, tako da tvori ustrezno karboksilno kislino (približno 60 % izločene učinkovine), in sekundarno s hidroksilacijo propilne stranske verige (približno 30 % izločene učinkovine).
Additional graduations at 0.25 ml and 0.75 ml starting at 0.25 ml up to 5 ml are shown. 
Prikazane so dodatne graduacijske oznake za 0,25 ml in 0,75 ml, ki se začnejo pri 0,25 ml do 5 ml.
If you have been told by your doctor that you cannot tolerate or digest some sugars, contact your doctor before taking this medicine. 
Če vam je zdravnik povedal, da ne prenašate ali prebavljate nekaterih sladkorjev, se pred uporabo tega zdravila posvetujte s svojim zdravnikom.
In juvenile dogs, the brivaracetam-induced changes at the exposure level 6- fold the clinical AUC were similar to those observed in adult animals. 
Pri mladičih psov so bile spremembe, ki jih je povzročil brivaracetam s stopnjo izpostavljenosti, ki je bila 6-krat višja od klinične AUC, podobne spremembam, opaženim pri odraslih živalih.